Pulmonary Fibrosis Treated with Inhaled @entity379 ( XXXX ).

@entity1 @entity17351 @entity3794 @entity2631 @entity2416 @entity358 @entity379 @entity2772
UNASSIGNED: Parenteral @entity379 was unsuccessful as a treatment for @entity3794 . Inhaled @entity379 targeted to the lungs may be more effective. Our @entity1 , a 56-year-old male with biopsy proven @entity2416 ( @entity2416 ) and declining pulmonary function tests (PFTs) was initially diagnosed with @entity2416 ( @entity2416 ). He enrolled in a 2-year research protocol and was treated with inhaled @entity2772 times per week. After completion of the protocol, he was able to secure the drug and continued therapy for a total of 7 years. He felt better, returning to work. His only complaint was transient cough during inhalation. PFTs improved (e.g., DLCO, 58% at baseline, 81% at 2 years, 69% currently). Clinical monitoring showed preserved exercise tolerance and stable CT scans. He was ultimately diagnosed (year 5) with @entity2631 -like connective tissue disease after he developed @entity17351 and a positive antinuclear antibody. Inhaled @entity379 was well tolerated for 7 years and may stabilize @entity358 .
